Patients with high-grade prostate cancer and low levels of prostate-specific antigen (PSA) have an unfavorable prognosis when compared with patients with high-grade prostate cancer with elevated PSA levels.
1-6 The reason for this observation is supported by the genomic characterization of these high-grade prostate cancers with low levels of PSA (<4 ng/mL; to convert to μg/L, multiply by 1.0) revealing genomic signatures that are associated with both resistance to testosterone suppression and a higher propensity to harbor micrometastatic disease at presentation.
7 Therefore, for these patients, an improved treatment paradigm is needed.